Notice concerning the impact of the 2026 Kumamoto Earthquake: Resumption of production at 三和化学研究所's Kumamoto Plant
株式会社三和化学研究所 (a subsidiary of SUZUKEN CO.,LTD.)
三和化学研究所 Kumamoto Plant
Damage to part of the buildings and manufacturing equipment caused by the 2026 Kumamoto Earthquake, which occurred on 28 July 2026
Company response
Operations and production at 三和化学研究所's Kumamoto Plant
19 October 2026 (Monday)
The production plan will be reviewed as necessary, and efforts will be made to restore normal operations as soon as possible. For contract-manufactured products, the company will work with each commissioning company to ensure stable supply. The company will continue to strengthen its production capabilities, giving top priority to safety and quality at the Kumamoto Plant.
| Item | Details |
|---|---|
| Event name | Notice concerning the impact of the 2026 Kumamoto Earthquake: Resumption of production at 三和化学研究所's Kumamoto Plant |
| Date of occurrence | 28 July 2026 |
| Subject Entity | 株式会社三和化学研究所 (a subsidiary of SUZUKEN CO.,LTD.) |
| Target Locations / Products | 三和化学研究所 Kumamoto Plant |
| Cause | Damage to part of the buildings and manufacturing equipment caused by the 2026 Kumamoto Earthquake, which occurred on 28 July 2026 |
| Suspended operations | Operations and production at 三和化学研究所's Kumamoto Plant |
| Scheduled resumption date | 19 October 2026 (Monday) |
| Outlook | The production plan will be reviewed as necessary, and efforts will be made to restore normal operations as soon as possible. For contract-manufactured products, the company will work with each commissioning company to ensure stable supply. The company will continue to strengthen its production capabilities, giving top priority to safety and quality at the Kumamoto Plant. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Inspections, repairs and safety checks for the buildings and manufacturing equipment damaged by the earthquake, as well as measures in compliance with Good Manufacturing Practice (GMP) for pharmaceuticals, have been completed, and the conditions required to resume production are now in place.